Effect of lapatinib on oral digoxin absorption in patients

Kevin M. Koch, Deborah A. Smith, Jeff Botbyl, Nikita Arya, Linda P. Briley, Leanne Cartee, Jane Holshouser White, Jennifer Beyer, Mohammed M. Dar, Hyuncheol Chung, Quincy Chu, Yung Jue Bang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The potential for an interaction between lapatinib and absorption of the P-glycoprotein (ABCB1) substrate digoxin at a therapeutic dose in breast cancer patients was characterized. Seventeen women with HER2-positive metastatic breast cancer received a single oral 0.5-mg dose of digoxin on days 1 and 9 and oral lapatinib 1500 mg once daily on days 2 through 9. Digoxin pharmacokinetic parameters were determined on day 1 (digoxin administration alone) and on day 9 (coadministration of lapatinib and digoxin), and parameters were compared to determine the effects of lapatinib on digoxin absorption. Concomitant medications that could affect ABCB1 were accounted for. Lapatinib 1500mg/day increased digoxin absorption approximately 80%, implicating lapatinib inhibition of intestinal ABCB1-mediated efflux. In summary, coadministration of lapatinib with narrow therapeutic index drugs that are substrates of ABCB1 should be undertaken with caution and dose adjustment should be considered.

Original languageEnglish
Pages (from-to)449-453
Number of pages5
JournalClinical Pharmacology in Drug Development
Volume4
Issue number6
DOIs
Publication statusPublished - 2015 Nov 1

Fingerprint

Digoxin
Breast Neoplasms
P-Glycoprotein
lapatinib
Pharmacokinetics
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

Koch, K. M., Smith, D. A., Botbyl, J., Arya, N., Briley, L. P., Cartee, L., ... Bang, Y. J. (2015). Effect of lapatinib on oral digoxin absorption in patients. Clinical Pharmacology in Drug Development, 4(6), 449-453. https://doi.org/10.1002/cpdd.189
Koch, Kevin M. ; Smith, Deborah A. ; Botbyl, Jeff ; Arya, Nikita ; Briley, Linda P. ; Cartee, Leanne ; White, Jane Holshouser ; Beyer, Jennifer ; Dar, Mohammed M. ; Chung, Hyuncheol ; Chu, Quincy ; Bang, Yung Jue. / Effect of lapatinib on oral digoxin absorption in patients. In: Clinical Pharmacology in Drug Development. 2015 ; Vol. 4, No. 6. pp. 449-453.
@article{0481aa5a4a6f484486eb77b037992f9d,
title = "Effect of lapatinib on oral digoxin absorption in patients",
abstract = "The potential for an interaction between lapatinib and absorption of the P-glycoprotein (ABCB1) substrate digoxin at a therapeutic dose in breast cancer patients was characterized. Seventeen women with HER2-positive metastatic breast cancer received a single oral 0.5-mg dose of digoxin on days 1 and 9 and oral lapatinib 1500 mg once daily on days 2 through 9. Digoxin pharmacokinetic parameters were determined on day 1 (digoxin administration alone) and on day 9 (coadministration of lapatinib and digoxin), and parameters were compared to determine the effects of lapatinib on digoxin absorption. Concomitant medications that could affect ABCB1 were accounted for. Lapatinib 1500mg/day increased digoxin absorption approximately 80{\%}, implicating lapatinib inhibition of intestinal ABCB1-mediated efflux. In summary, coadministration of lapatinib with narrow therapeutic index drugs that are substrates of ABCB1 should be undertaken with caution and dose adjustment should be considered.",
author = "Koch, {Kevin M.} and Smith, {Deborah A.} and Jeff Botbyl and Nikita Arya and Briley, {Linda P.} and Leanne Cartee and White, {Jane Holshouser} and Jennifer Beyer and Dar, {Mohammed M.} and Hyuncheol Chung and Quincy Chu and Bang, {Yung Jue}",
year = "2015",
month = "11",
day = "1",
doi = "10.1002/cpdd.189",
language = "English",
volume = "4",
pages = "449--453",
journal = "Clinical Pharmacology in Drug Development",
issn = "2160-763X",
publisher = "Sage Periodicals Press",
number = "6",

}

Koch, KM, Smith, DA, Botbyl, J, Arya, N, Briley, LP, Cartee, L, White, JH, Beyer, J, Dar, MM, Chung, H, Chu, Q & Bang, YJ 2015, 'Effect of lapatinib on oral digoxin absorption in patients', Clinical Pharmacology in Drug Development, vol. 4, no. 6, pp. 449-453. https://doi.org/10.1002/cpdd.189

Effect of lapatinib on oral digoxin absorption in patients. / Koch, Kevin M.; Smith, Deborah A.; Botbyl, Jeff; Arya, Nikita; Briley, Linda P.; Cartee, Leanne; White, Jane Holshouser; Beyer, Jennifer; Dar, Mohammed M.; Chung, Hyuncheol; Chu, Quincy; Bang, Yung Jue.

In: Clinical Pharmacology in Drug Development, Vol. 4, No. 6, 01.11.2015, p. 449-453.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of lapatinib on oral digoxin absorption in patients

AU - Koch, Kevin M.

AU - Smith, Deborah A.

AU - Botbyl, Jeff

AU - Arya, Nikita

AU - Briley, Linda P.

AU - Cartee, Leanne

AU - White, Jane Holshouser

AU - Beyer, Jennifer

AU - Dar, Mohammed M.

AU - Chung, Hyuncheol

AU - Chu, Quincy

AU - Bang, Yung Jue

PY - 2015/11/1

Y1 - 2015/11/1

N2 - The potential for an interaction between lapatinib and absorption of the P-glycoprotein (ABCB1) substrate digoxin at a therapeutic dose in breast cancer patients was characterized. Seventeen women with HER2-positive metastatic breast cancer received a single oral 0.5-mg dose of digoxin on days 1 and 9 and oral lapatinib 1500 mg once daily on days 2 through 9. Digoxin pharmacokinetic parameters were determined on day 1 (digoxin administration alone) and on day 9 (coadministration of lapatinib and digoxin), and parameters were compared to determine the effects of lapatinib on digoxin absorption. Concomitant medications that could affect ABCB1 were accounted for. Lapatinib 1500mg/day increased digoxin absorption approximately 80%, implicating lapatinib inhibition of intestinal ABCB1-mediated efflux. In summary, coadministration of lapatinib with narrow therapeutic index drugs that are substrates of ABCB1 should be undertaken with caution and dose adjustment should be considered.

AB - The potential for an interaction between lapatinib and absorption of the P-glycoprotein (ABCB1) substrate digoxin at a therapeutic dose in breast cancer patients was characterized. Seventeen women with HER2-positive metastatic breast cancer received a single oral 0.5-mg dose of digoxin on days 1 and 9 and oral lapatinib 1500 mg once daily on days 2 through 9. Digoxin pharmacokinetic parameters were determined on day 1 (digoxin administration alone) and on day 9 (coadministration of lapatinib and digoxin), and parameters were compared to determine the effects of lapatinib on digoxin absorption. Concomitant medications that could affect ABCB1 were accounted for. Lapatinib 1500mg/day increased digoxin absorption approximately 80%, implicating lapatinib inhibition of intestinal ABCB1-mediated efflux. In summary, coadministration of lapatinib with narrow therapeutic index drugs that are substrates of ABCB1 should be undertaken with caution and dose adjustment should be considered.

UR - http://www.scopus.com/inward/record.url?scp=84954218000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954218000&partnerID=8YFLogxK

U2 - 10.1002/cpdd.189

DO - 10.1002/cpdd.189

M3 - Article

VL - 4

SP - 449

EP - 453

JO - Clinical Pharmacology in Drug Development

JF - Clinical Pharmacology in Drug Development

SN - 2160-763X

IS - 6

ER -

Koch KM, Smith DA, Botbyl J, Arya N, Briley LP, Cartee L et al. Effect of lapatinib on oral digoxin absorption in patients. Clinical Pharmacology in Drug Development. 2015 Nov 1;4(6):449-453. https://doi.org/10.1002/cpdd.189